Qualigen Therapeutics Inc.
QLGN | NASDAQ
$3.21
$0.00 (0.00%)
Nov 2, 2026, 3:56 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 5.2M | 4.98M | 5.65M | 4.31M |
Cost of Revenue | n/a | n/a | 5.21M | 4.3M | 4.33M | 7.19M |
Gross Profit | n/a | n/a | -4.5K | 680.8K | 1.32M | -2.88M |
Operating Income | -13.2M | -5.76M | -11.3M | -17.94M | -22.66M | -12.68M |
Interest Income | 742.02K | 128.8K | n/a | n/a | 42.69K | 138.8K |
Pretax Income | -16.97M | -6.15M | -12.48M | -21.3M | -17.89M | -20.42M |
Net Income | -19.53M | -6.16M | -13.42M | -21.03M | -17.9M | -20.42M |
Selling & General & Admin | 8.82M | 4.2M | 6.09M | 11.79M | 12.27M | 8.42M |
Research & Development | 184.8K | 1.2M | 5.21M | 6.84M | 11.72M | 3.55M |
Other Expenses | 4.2M | 360K | -5.21M | 1.13K | 5.45K | -2.18M |
Operating Expenses | 13.2M | 5.76M | 6.1M | 18.62M | 23.98M | 9.8M |
Interest Expense | 988.5K | 908.94K | 1.52M | 34.4K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | -4.5K | 950.42K | 542.59K | 400.17K |
Cost & Expenses | 13.2M | 5.76M | 11.3M | 22.93M | 28.32M | 16.99M |
Income Tax Expense | 2.56M | 6.33K | -4.79K | -265.07K | 5.43K | -619 |
Shares Outstanding (Basic) | 2.41M | 361.59K | 5.07M | 3.84M | 2.93M | 2.56M |
Shares Outstanding (Diluted) | 2.41M | 361.59K | 5.07M | 3.84M | 2.93M | 2.59M |
EPS (Basic) | -8.11 | -17.28 | -2.46 | -5.48 | -6.10 | -7.98 |
EPS (Diluted) | -8.11 | -17.28 | -2.46 | -5.48 | -6.10 | -7.89 |
EBITDA | -13.2M | -5.24M | -11.3M | -13.84M | -22.34M | -11.16M |
EBIT | -13.2M | -5.24M | -11.3M | -13.85M | -22.66M | -11.3M |
Depreciation & Amortization | n/a | n/a | 4.5K | 12.17K | 322.06K | 138.65K |
Add to Watchlist
Select watchlists to add or remove QLGN